Wednesday, June 29, 2022
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

Never the same again: How COVID-19 created seismic change in global life sciences regulations

in Opinion
Never the same again: how covid-19 created seismic change in global life sciences regulations
Share on FacebookShare on Twitter

While COVID-19 introduced many global challenges in the life sciences industry, it also brought accelerated global scientific and regulatory collaborations and innovations. In our new extensive report, you’ll discover the impact of COVID-19 on the life sciences industry, what has been accomplished by the industry and its regulators globally, and what opportunities may emerge going forward.

On April 17, 2020, the National Institutes of Health (NIH) and its Foundation (FNIH) created the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program to develop an international strategy for a coordinated research response to COVID-19. Was this unprecedented level of collaboration a one-off, or will it continue across life sciences industry in the future?

As the industrial and regulatory landscape continues to evolve, it’s vital for stakeholders to have clarity on next steps to help them prepare their people and systems for the next global crisis.

With that in mind, the Global Regulatory Intelligence Team (GRIT) at Deloitte has created an in-depth report, “Never the same again: How COVID-19 created seismic change in life sciences regulations.” Our subject-matter specialists on the ground, leveraging long-term relationships and in-depth research spanning in time from the onset of the pandemic to March 2021, co-wrote this life sciences industry report that richly integrates global insights and relevant findings. In it, they share what fundamentally changed in life sciences regulation through a prism of five of the world’s most populous economies and largest life sciences markets—the United States, China, the European Union, Japan, and India.

Addressing four facets of the new global life sciences regulatory landscape

Given the expansive scope of the report, we have focused the report around four key areas: governments declaring health emergencies, regulators collaborating with companies, regulatory agencies collaborating across borders, and companies collaborating with each other.

Governments declared health emergencies

A declaration of a public health emergency positions a country’s decision-makers to enact extraordinary measures. Those measures impact citizens’ behavior as well as regulatory governmental agencies, life sciences companies, and the health care industry. As our report reveals, one common effect was enabling governments to deploy a whole-of-government approach (to various degrees) to enact public health measures as well as steps that impacted life sciences industry supply chains and working arrangements. Regulatory agencies and industry responses soon followed, shaping the transition to operating in “crisis mode.”

Into the future, together: a report written through a global prism

Our life sciences industry report takes a deep dive by region and shows how each country’s responses varied in approach, timing, intensity, and effectiveness. Here are just a few snapshots of the findings we uncovered globally.

United States:
• Regulatory modifications by US regulators triggered enhanced responses to the pandemic, such as relaxing clinical trial application (CTA) provisions to accelerate the administrative process.
• Unlike ever before, several large pharmaceutical companies, including Eli Lilly, Novartis, Gilead, and AstraZeneca, formed a group called COVID R&D to share knowledge and resources.

China:
• In January 2020, the genome sequence of the virus was isolated in China, and Chinese regulators soon shared the research results with the WHO for global research purposes.
• Manufacturers and distributors collaborated with Central and provincial governments on volume-based procurement (VBP) of drugs that have passed their patent protection period.

European Union:
• The EU European Medicines Agency (EMA) established a pandemic task force to accelerate the development, authorization, and monitoring of COVID-19 treatments and vaccines
• EMA collaborated with the US Food and Drug Administration to exchange information on products and clinical trials and jointly interpreted data supporting regulatory decisions.

Japan:
• The Ministry of Health, Labour and Welfare (MHLW) collaborated with industry groups to stabilize supplies of essential items in response to the declaration of a state of emergency.
• Pharmaceuticals and Medical Devices Agency (PMDA)—the regulatory authority for medical devices, vaccines, and drugs in Japan—introduced several regulatory changes that supported life sciences.

India:
• India responded by establishing a regulatory framework for rapid COVID-19 response, including fast-tracking the approval process for vaccines, diagnostics, prophylactics, and therapeutics.
• In May 2020, the Ministry of Health and Family Welfare set up an approval system permitting applicants to manufacture and stock COVID-19 vaccines under clinical trial.

Moving forward, with caution and vision

As the industry continues to ponder the global impacts of new regulatory regimes, now is the time to understand how your priorities were set, examine ways in which communication changed, assess how impacts were absorbed, and be ready to respond more effectively to future crises.

Download “Never the same again: How COVID-19 created seismic change in life sciences regulations” today and gain clarifying insights that may help you collaborate better, accelerate innovation, and expand.

Tags: COVID-19Life sciences

Related Posts

Automaker ceos urge congress to lift ev tax credit cap
Opinion

A New Era for Fuel Retailers

Collaborative advantage: activating the power of many
Opinion

Collaborative Advantage: Activating the Power of Many

Why locking in subscribers is bad for business
Opinion

Why Locking In Subscribers Is Bad for Business

Smart cities, smarter public health
Opinion

Smart Cities, Smarter Public Health

Standing still is not an option
Opinion

Standing Still Is Not an Option

What can we learn from the last recession?
Opinion

What Can We Learn From the Last Recession?

How is your bottom line linked to your workers’ finances?
Opinion

How is Your Bottom Line Linked to Your Workers’ Finances?

How us tax policy is shrinking the labor share
Business

How US Tax Policy Is Shrinking the Labor Share

How to manage risks from geopolitical and related crises
Opinion

How to Manage Risks from Geopolitical and Related Crises

What utilities can do to secure the emobility future — and their own
Opinion

What Utilities Can Do to Secure the eMobility Future — and Their Own

No Result
View All Result

Recent Posts

  • A New Era for Fuel Retailers
  • The U.S. Economy Shrank 1.6% in the First Quarter
  • Crypto Hedge Fund Three Arrows Capital Falls into Liquidation
  • Bed Bath & Beyond Replaces CEO Mark Tritton
  • Martin Kropelnicki, CEO California Water Service Group One Team, the Same Direction

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    CEO Latin America | ES

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

     

    AUSTIN

    600, Congress Avenue 14th Floor
    Austin, TX.
    78701
    USA
    +1 512 649 0340

    NEW YORK

    387 Park Ave South,
    New York, NY.
    10016
    USA
    +1 212 796 64 15

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2022 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In
    Are you sure want to unlock this post?
    Unlock left : 0
    Are you sure want to cancel subscription?